Calithera Biosciences Inc (NASDAQ:CALA) Insider Acquires $379,487.90 in Stock

Calithera Biosciences Inc (NASDAQ:CALA) insider Value Fund L. P. Biotechnology purchased 88,253 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were acquired at an average cost of $4.30 per share, for a total transaction of $379,487.90.

NASDAQ:CALA traded down $0.16 on Friday, hitting $4.05. 553,981 shares of the company’s stock were exchanged, compared to its average volume of 308,000. The firm has a 50-day moving average price of $3.02 and a 200-day moving average price of $4.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.39 and a quick ratio of 7.39. Calithera Biosciences Inc has a 52 week low of $2.45 and a 52 week high of $6.90. The company has a market cap of $207.57 million, a P/E ratio of -2.72 and a beta of 1.81.

Calithera Biosciences (NASDAQ:CALA) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.07. On average, research analysts expect that Calithera Biosciences Inc will post -1.92 earnings per share for the current fiscal year.

Several brokerages have commented on CALA. Zacks Investment Research raised shares of Calithera Biosciences from a “sell” rating to a “hold” rating in a research report on Monday. Citigroup set a $8.00 price target on shares of Calithera Biosciences and gave the stock a “hold” rating in a research report on Friday, August 9th. HC Wainwright began coverage on shares of Calithera Biosciences in a research report on Tuesday. They set a “buy” rating and a $7.00 price target on the stock. Finally, ValuEngine cut shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $6.50.

Several hedge funds have recently modified their holdings of the company. Grimes & Company Inc. bought a new stake in shares of Calithera Biosciences in the 3rd quarter valued at about $63,000. Rhumbline Advisers raised its holdings in shares of Calithera Biosciences by 18.8% in the 3rd quarter. Rhumbline Advisers now owns 58,413 shares of the biotechnology company’s stock valued at $180,000 after purchasing an additional 9,235 shares during the period. Wedbush Securities Inc. bought a new stake in shares of Calithera Biosciences in the 3rd quarter valued at about $42,000. Magnetar Financial LLC bought a new stake in shares of Calithera Biosciences in the 2nd quarter valued at about $232,000. Finally, Walleye Trading Advisors LLC bought a new stake in shares of Calithera Biosciences in the 2nd quarter valued at about $146,000. 65.31% of the stock is currently owned by institutional investors.

About Calithera Biosciences

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Further Reading: What are the components of an earnings report?

Insider Buying and Selling by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.